Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | HTT | P42858 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.49 |
| ▸ | PABPC1 | P11940 | 3/20 | 0.49 |
| ▸ | EIF4H | Q15056 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11169568 | 0.88 | KDM4E (0.52) | MEN1KMT2AALDH1A1LMNAHTT | |
| SCHEMBL2002464 | 0.87 | HTR1A (0.58) | HTTSMN1; SMN2HDAC6PABPC1 | |
| SCHEMBL15453221 | 0.78 | PABPC1 (0.59) | MEN1KMT2AALDH1A1PABPC1KDM4E | |
| SCHEMBL29506423 | 0.78 | PABPC1 (0.59) | MEN1KMT2AALDH1A1PABPC1KDM4E | |
| SCHEMBL27857992 | 0.76 | ALDH1A1 (0.63) | MEN1KMT2AALDH1A1LMNAHTT | |
| SCHEMBL28256934 | 0.76 | PABPC1 (0.39) | MEN1KMT2AL3MBTL1PABPC1TSHR | |
| SCHEMBL2478157 | 0.76 | MEN1 (0.57) | MEN1KMT2AALDH1A1LMNAHTT | |
| SCHEMBL30504562 | 0.76 | MEN1 (0.57) | MEN1KMT2AALDH1A1LMNAHTT | |
| SCHEMBL2736333 | 0.76 | MEN1 (0.62) | MEN1KMT2AALDH1A1LMNAHTT | |
| SCHEMBL29260245 | 0.76 | MEN1 (0.57) | MEN1KMT2AALDH1A1LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108699065-A | Tricyclic compounds and composition as kinase inhibitor | 诺华股份有限公司 | 2018-10-23 | — | — | CN | disclosed |
| CN-108203433-A | A kind of ROCK inhibitor and its application | 成都先导药物开发有限公司 | 2018-06-26 | — | — | CN | disclosed |
| CN-107072205-A | SMYD inhibitors | EPIZYME股份有限公司 | 2017-08-18 | — | — | CN | disclosed |
| EP-2275433-B1 | METASTIN DERIVATIVE AND USE THEREOF | UNIV KYOTO (JP) | 2017-06-07 | — | — | EP | disclosed |
| CN-106103485-A | Antibody molecules to PD-1 and uses thereof | 达纳-法伯癌症研究公司 | 2016-11-09 | — | — | CN | disclosed |
| US-8778871-B2 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-07-15 | — | — | US | disclosed |
| US-8765909-B2 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-07-01 | — | — | US | disclosed |
| US-8592379-B2 | Metastin derivative and use thereof | KYOTO UNIVERSITY (JP) | 2013-11-26 | — | — | US | disclosed |
| US-8361968-B2 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-01-29 | — | — | US | disclosed |
| US-8115027-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2012-02-14 | — | — | US | disclosed |
| EP-1664024-B1 | SYNTHESIS OF QUINOLINE 5-CARBOXAMIDES USEFUL FOR THE PREPARATION OF PDE IV INHIBITORS | SCHERING CORP (US) | 2007-07-11 | — | — | EP | disclosed |
| EP-1758932-A2 | METASTIN DERIVATIVES AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2007-03-07 | — | — | EP | disclosed |
| CN-1878765-A | Synthesis of quinoline 5-carboxamides useful for the preparation of PDE IV inhibitors | SCHERING CORP (US) | 2006-12-13 | — | — | CN | disclosed |
| US-7129357-B2 | Synthesis of quinoline 5-carboxamides useful for the preparation of PDE IV inhibitors | SCHERING CORPORATION (US) | 2006-10-31 | — | — | US | disclosed |
| US-20060241051-A1 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-10-26 | — | — | US | disclosed |
| EP-1664024-A1 | SYNTHESIS OF QUINOLINE 5-CARBOXAMIDES USEFUL FOR THE PREPARATION OF PDE IV INHIBITORS | SCHERING CORPORATION (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2006001499-A2 | METASTIN DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-05 | — | — | WO | disclosed |
| EP-1577323-A1 | METASTIN DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2005-09-21 | — | — | EP | disclosed |
| US-20050124655-A1 | Synthesis of quinoline 5-carboxamides useful for the preparation of PDE IV inhibitors | SCHERING CORPORATION | 2005-06-09 | — | — | US | disclosed |
| WO-2005028471-A1 | SYNTHESIS OF QUINOLINE 5-CARBOXAMIDES USEFUL FOR THE PREPARATION OF PDE IV INHIBITORS | SCHERING CORPORATION (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124655-A1 | Synthesis of quinoline 5-carboxamides useful for the preparation of PDE IV inhibitors | PDE3B, PDE4A, PDE5A | MEN1 2542/4885KMT2A 332/4885ALDH1A1 674/4885 |
| US-20060241051-A1 | Metastin derivatives and use thereof | MET, HGFAC, HGF | MEN1 7/4885KMT2A 2993/4885ALDH1A1 2662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.